
Thanks to all our participants. @Bweber04 @amitvkhera @jctardif_mhi @AllanLKleinMD1 @DrMichaelShapir @NehalMehtaMD
This tweet is unavailable


Thanks to all our participants. @Bweber04 @amitvkhera @jctardif_mhi @AllanLKleinMD1 @DrMichaelShapir @NehalMehtaMD
This tweet is unavailable

Nice to see a former star @NYULH_DeptofMed Cardiology fellow evolve from trainee himself into the senior author and mentor of a current fellow. The virtuous cycle at its best.

At #ScientificSessions26 it is great to meet up with friends @cwojcik @MWilkinsonMD @garshick and crew

Amazing @nyulangone cardiology colleagues at #AHA26

NYU Langone Cardiology making its mark at #ScientificSessions26! It’s a wonderful forum to share research, exchange ideas, and connect with colleagues across the field, including Dr. Jennifer Mieres. What an exceptional group representing the cardiology community!🫀

Starting tomorrow! 🫀🔥 Follow #CVinflame2026 + Dr. Rafael Toro (@RafaelEToroM), CardioNerds Conference Scholar, for live updates from the 6th Annual North American #CardioRheum Symposium. Still need to register? ⤵️ nyulmc.org/cvinflammationcme @CardioNerds @garshick @Bweber04
Tomorrow is the day! The 6th Annual Cardiometabolic Risk in Inflammatory Conditions Symposium is here. Stay tuned for live highlights and key takeaways! #CVinflame2026 @NYUCVDPrevent @garshick @Bweber04 @CardioNerds

🔎Spotlight on Sjögren’s at our #CardioRheumatology CME! Sjögren’s expert Teja Kapoor, MD will review the comprehensive systemic and cardiovascular manifestations of Sjögren’s. Sign up here ⤵️ nyulmc.org/cvinflammationcme

🥊 It’s debate ⏰ time. See top 🫀 cardiology minds go head-to-head on today’s toughest questions at #HeartofCardio 2026 in Miami Beach. 🔗 heartofcardio.com/ Join dream team: @ba_steinberg | @ChiadiNdumele | @MCoylewright | @AJBloodMD | @manesh_patelMD | @HeartDocSadiya | @garshick

Check out the latest review in the Jan 16th issue of @CircRes by @IntmedAbel & colleagues "A Road Map to Understanding #CVD in #Diabetes" at ahajrnls.org/4b6JCJg @SaumyaDas_Lab @naomihamburg @ChiaraGiannare1 @jdnewmanMDMPH @lab_ej @ddbergMD @garshick

Excited to share our @JACCJournals #JACCIMG paper led by ⭐️@Bweber04 on AI detection of CAC on chest CT among 2,546 individuals with IMID (SLE/RA/Psoriasis) who did not have hx of ASCVD ~50% had CAC --> most not on statin! ➡️Over 8 yrs, AI CAC provided robust a/w MACE + ACM

How do statins enhance endothelial health & reduce #inflammation? Dr. Michael Garshick will present important findings from the Cardiometabolic Health Strategically Focused Research Network. Mon, 11/10, 11:06-11:11 AM Basic Sci Zone Moderated Digital Poster 26: VB.MDP.16

Register for the 5th Annual #CardioRheum symposium and get free access to Medscape’s 1 hour mini-symposium: ‘Race Against Inflammation: ASCVD & #CKD Risk Reduction Insights.’ Join in-person or virtually—don’t miss the main event + bonus content! Sign up: nyulmc.org/cvinflammationcme

2/Psoriasis is a skin disease that causes inflammation, and it’s been linked to heart problems. Michael Garshick, MD, director of the Cardio-Rheumatology Program, explores how inflammation in psoriasis may promote plaque buildup in arteries. 📍Sat, 11AM CT | Session 1041

NYU Langone cardiology faculty kick off #ACC25 in style! Stay tuned for exciting conference updates from @nyugrossman, highlighting the latest in #cardiovascular research and innovation.

👉Two great manuscripts about inflammation and CVD 🔓Open Access 1️⃣Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases ☝️This review summarizes the main characteristics and findings of completed and upcoming randomized controlled trials directly targeting inflammation in CVDs, and discusses major challenges and future perspectives in the exciting and constantly expanding landscape of cardioimmunology ahajournals.org/doi/full/10.… 2️⃣ Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay ☝️ This review aims to critically evaluate the current understanding of the relationship between immune-mediated inflammatory diseases and dyslipidemia, the underlying mechanisms contributing to atherogenesis, and the impact of various pharmacotherapies on lipid profiles and cardiovascular risk. We also discuss the role of lipid-lowering therapies, particularly statins, in managing residual risk in this high-risk population and explore the potential of emerging therapies with complementary anti-inflammatory and lipid-lowering effects. ahajournals.org/doi/full/10.… @society_eas @atvbahajournals

Thanks Joel for highlighting our work!. @NPF @PskinPscientist @DrJoelGelfand @NYUCVDPrevent @Bweber04 @nyulangone